Axsome Therapeutics rises after Q2 revenue beat

Axsome Therapeutics

04/08/2025 12:41

** Shares of drugmaker Axsome Therapeutics AXSM.O rise 5.9% to $108.98 premarket

** Company reports Q2 revenue of $150 mln, higher than analysts' estimate of $138.8 mln, according to data compiled by LSEG

** Says sales of its depression drug Auvelity were $119.6 mln in Q2, up 84% from $65 mln a year ago

     ** Reports Q2 net loss per share of 97 cents, less than loss of $1.67 per share a year earlier

** Up to last close, stock up 21.8% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))